Concerns Rise Among Biotech Leaders Over FDA Leadership Changes and Their Effects on Rare Disease Drugs
The recent departure of significant FDA officials has sparked worries among biotech executives about the future of rare disease drug development, emphasizing the need for regulatory stability.
Editorial Staff 24 days ago